STAT3 and urinary bladder carcinoma: Given STAT3 represents a promising target for cancer therapeutics [15,19], the likelihood that sertindole generally targets the STAT3 signaling axis in cancer cells confers a promising translation potential to sertindole as an anticancer agent for the treatment of various human malignancies, including bladder cancer.